PRAX
Overvalued by 64.9% based on the discounted cash flow analysis.
Market cap | $781.15 Million |
---|---|
Enterprise Value | $616.65 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-10.21 |
Beta | 2.67 |
Outstanding Shares | 21,055,834 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -3.8 |
---|---|
PEG | -3.43 |
Price to Sales | - |
Price to Book Ratio | 1.92 |
Enterprise Value to Revenue | 384.21 |
Enterprise Value to EBIT | -3.75 |
Enterprise Value to Net Income | -5 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0 |
No data
No data
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying in...